Generic Entresto Sprinkle Availability
Last updated on Mar 13, 2025.
See also: Generic Entresto
Entresto Sprinkle is a brand name of sacubitril/valsartan, approved by the FDA in the following formulation(s):
ENTRESTO SPRINKLE (sacubitril; valsartan - capsule, pellets;oral)
Has a generic version of Entresto Sprinkle been approved?
No. There is currently no therapeutically equivalent version of Entresto Sprinkle available in the United States.
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Entresto Sprinkle. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: Generic Drug FAQ.
Related patents
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.
-
Galenic formulations of organic compounds
Patent 10,722,471
Issued: July 28, 2020
Inventor(s): Winzenburg Gesine & Trueby Bernd & Chen Fabian & Ayalasomayajula Surya Prakash & Bush Christopher & Berkhin Masha
Assignee(s): Novartis AGThe present invention relates to a solid unit oral dosage form comprising sacubitril and valsartan in a 1:1 molar ratio, preferably in the form of the so-called angiotensin receptor neprilysin inhibitor (ARNI) LCZ696, which is a complex salt hydrate of sacubitril, valsartan, and sodium ions, appropriate for use in pediatrics or other patients where low and individual dosing is required or who encounter problems with swallowing e.g. as a result of a disease or because of age, to the manufacture of said solid dosage form and to invention embodiments relating to therapy using said dosage form.
Patent expiration dates:
- February 2, 2037✓✓
- February 2, 2037
-
Methods of treatment and pharmaceutical composition
Patent 8,101,659
Issued: January 24, 2012
Inventor(s): Ksander Gary M & Webb Randy L
Assignee(s): Novartis AGThe invention relates a pharmaceutical composition comprising a combination of:
Patent expiration dates:
- January 15, 2025✓
- January 15, 2025
-
Compounds containing S-N-valeryl-N-{[2′-(1H-tetrazole-5-yl)-biphenyl-4-yl]-methyl}-valine and (2R,4S)-5-biphenyl-4-yl-4-(3-carboxy-propionylamino)-2-methyl-pentanoic acid ethyl ester moieties and cations
Patent 8,877,938
Issued: November 4, 2014
Inventor(s): Feng Lili & Godtfredsen Sven Erik & Hu Bin & Liu Yugang & Karpinski Piotr & Sutton Paul Allen & Prashad Mahavir & Girgis Michael J. & Blacklock Thomas J.
Assignee(s): Novartis Pharmaceuticals CorporationA compound of an angiotensin receptor antagonist (ARB), a neutral endopeptidase inhibitor (NEPi) and one or more monovalent cations are useful for the treatment of hypertension and/or heart failure. ARB includes S—N-valeryl-N-{[2′-(1H-tetrazole-5-yl)-biphenyl-4-yl]-methyl}-valine in the anion form, NEPi includes (2R,4S)-5-biphenyl-4-yl-4-(3-carboxy-propionylamino)-2-methyl-pentanoic acid ethyl ester in the anion form and cation includes monovalent cations such as Na. The compound includes trisodium [3-((1S,3R)-1-biphenyl-4-ylmethyl-3-ethoxycarbonyl-1-butylcarbamoyl)propionate-(S)-3′-methyl-2′-(pentanoyl{2″-(tetrazol-5-ylate)biphenyl-4′-ylmethyl}amino)butyrate] hemipentahydrate.
Patent expiration dates:
- May 27, 2027✓✓
- May 27, 2027
-
Compounds containing S-N-valeryl-N-{[2′-(1H-tetrazole-5-yl)-biphenyl-4-yl]-methyl)-valine and (2R,4S)-5-biphenyl-4-yl-4-(3-carboxy-propionylamino)-2-methyl-pentanoic acid ethyl ester moieties and cations
Patent 9,388,134
Issued: July 12, 2016
Inventor(s): Feng Lili & Godtfredsen Sven Erik & Sutton Paul Allen & Prashad Mahavir & Girgis Michael J. & Hu Bin & Liu Yugang & Blacklock Thomas J. & Karpinski Piotr Henryk
Assignee(s): NOVARTIS, AGA method for treatment of a cardiovascular or renal condition or disease with a specific combination, linked pro-drug or a compound of an angiotensin receptor antagonist and a NEPi.
Patent expiration dates:
- November 8, 2026✓
- November 8, 2026
More about Entresto Sprinkle (sacubitril / valsartan)
- Check interactions
- Compare alternatives
- Pricing & coupons
- Imprints, shape & color data
- Side effects
- Dosage information
- During pregnancy
- Drug class: angiotensin receptor blockers and neprilysin inhibitors
- En español
Patient resources
Other brands
Professional resources
Other brands
Related treatment guides
Glossary
| Term | Definition |
|---|---|
| Drug Patent | A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation. |
| Drug Exclusivity | Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant. |
| RLD | A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.